EN002 / Enkang Pharma - LARVOL DELTA

First-in-human phase I/II study of EN002-gel, a first-in-class drip inhibitor, in non-melanoma skin cancer and actinic keratosis. (ASCO 2026) - P1/2 | "The Phase I/II studies provided clinical evidence of a favorable benefit-risk profile of a novel topical therapy for patients with BD, BCC, SCC or AK, who represent unmet medical needs. Phase II drug treatment for AK is expected to be completed in May 2026 and new results will be presented at this meeting."

First-in-human • P1/2 data • Actinic Keratosis • Basal Cell Carcinoma • Bowens Disease • Dermatology • Developmental Disorders • Genetic Disorders • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma

Safety and preliminary efficacy of a first-in-class DRIP inhibitor EN002 topical gel in non-melanoma skin cancer and actinic keratosis: An international phase I study (SID 2025) - "The phase 1 study provided preliminary clinical evidence of a favorable benefit-risk profile of a novel topical therapy for patients with naïve, recurrent or relapsed NMSC or AK, who represent unmet medical needs. In the ongoing Phase II study with expanded treatment duration, the first 4 enrolled patients all achieved 100% clearance in 9 weeks."

Clinical • Late-breaking abstract • P1 data • Actinic Keratosis • Basal Cell Carcinoma • Bowens Disease • Dermatology • Genetic Disorders • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer